1. India Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Vanta Bioscience Limited

Vanta Bioscience Limited

VANTABIO.BO
Vanta Bioscience LimitedIN flagBombay Stock Exchange
22.07
INR
- -
- -
156.96MMarket Cap
Vanta Bioscience Limited
VANTABIO.BO
(Bombay Stock Exchange)

Recent

price

22.07

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
6.96
19.68
22.41
15.9
15.35
9.94
15.4
3.11
Revenue per Share
- -
0.05
1.1
1.59
0.71
0.14
-10.27
-3.67
-7.56
Basic EPS, GAAP
-0.46
-20.27
-1.64
-7.94
-24.12
-18.86
-46.45
-1.14
-14.42
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
6.37
10.05
11.15
13.08
13.79
13.93
3.65
-0.02
-7.59
Book Value per Share
10.74
20.47
29.1
31.05
19.58
3.28
-24.82
-40.09
-65.3
Tangible Book Value per Share
6
6
6
6
6
6
6
6
6
Basic Weighted Avg Shares
- -
40
124
141
100
97
63
97
20
Sales/Revenue/Turnover
- -
13.8
24.27
22.49
27.37
22.22
-109.8
-32.58
-438.94
Operating Margin (%)
- -
6
7
12
13
13
27
45
44
Depreciation Expense
- -
- -
7
10
4
1
-65
-23
-48
Net Income, GAAP
- -
91.33
36.74
24.52
23.91
41.03
- -
- -
- -
Effective Tax Rate (%)
- -
0.68
5.61
7.1
4.48
0.91
-103.26
-23.82
-243.18
Profit Margin (%)
4
66
138
100
51
2
-25
-56
-112
Working Capital
75
100
122
137
278
370
471
489
541
LT Debt
62
166
232
245
262
293
189
130
38
Total Equity
- -
0.23
5.91
6.11
4.01
1.86
- -
- -
- -
Return on Invested Capital (%)
- -
0.3
8.94
10.21
5.49
2.99
- -
- -
- -
Return on Capital (%)
- -
0.58
10.89
13.14
5.3
1.01
-116.79
-53.77
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-23.74%
-70.84%
Free Cash Flow
- -
278.74%
1,162.94%
Net Income, GAAP
- -
-1,508.17%
106.18%
Sales/Revenue/Turnover
- -
-18.52%
-79.8%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
97
2025
- -
- -
- -
- -
20
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-3.67
2025
- -
- -
- -
- -
-7.56
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Sareum Holdings plc (SAR.L)
Tenax Therapeutics, Inc. (TENX)
Oncternal Therapeutics, Inc. (ONCT)
Recce Pharmaceuticals Ltd (RCE.AX)
Noxopharm Limited (NOX.AX)
CStone Pharmaceuticals (2616.HK)
Business
Vanta Bioscience Limited, an India-based preclinical contract research organization, provides GLP-compliant toxicology and safety assessment services to the pharmaceutical, medical devices, nutraceuticals, feed additives, biotech, agrochemicals, cosmetics, and chemical industries worldwide; core offerings include toxicology studies (genetic, animal, inhalation, and eco-toxicology), agro-chemical and chemical safety assessments, biocompatibility studies, diet formulation, batch release tests, medical devices testing, food additives evaluation, and cosmetics safety testing; the company also delivers risk assessment services for active pharmaceutical ingredients, excipients, extractables, leachables, and pharmaceutical impurities, along with determination of health-based exposure limits such as permitted daily exposure, allowable daily exposure, and occupational exposure limits. Founded in 2016 and headquartered in Secunderabad, Telangana, with operations centered in India and facilities near Chennai, Tamil Nadu, Vanta Bioscience conducts in vitro and in vivo studies compliant with OECD GLP, ISO, and USFDA GLP (21 CFR Part 58) guidelines to support regulatory submissions including IND filings. In recent developments, the company reported audited financial results for the half-year and year ended March 31, 2025, reflecting net losses with an unmodified audit opinion; it previously acquired subsidiaries Vanta Clinical Research Limited and Vayam Research Solutions Limited during 2018-19 to expand preclinical proof-of-concept capabilities, while Vayam ceased to be a step-down subsidiary following DCGI registration grant; additionally, board meetings in 2025 addressed financial approvals amid operational challenges including high debtor days and negative sales growth.